Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment-Reference-Cited by-同舟云学术

Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment

Published:2021-03-04 Issue:3 Volume:17 Page:285-300
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Otero-Romero Susana¹,Sánchez-Montalvá Adrián²³,Vidal-Jordana Angela⁴

Affiliation:

1. Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d’Hebron, Barcelona, Spain

2. Department of Infectious Diseases. Hospital Universitari Vall d’Hebron, International Health Program Catalan Institute of Health (PROSICS), Universitat Autònoma De Barcelona, Barcelona, Spain

3. Micobacteria Infections Study Group (GEIM) of the Spanish Society of Infectious Diseases (SEIMC), Spain

4. Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat). Hospital Universitari Vall d’Hebron, Universitat Autònoma De Barcelona, Barcelona, Spain

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2021.1886924

Reference144 articles.

1. Treatment of multiple sclerosis — success from bench to bedside

2. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis

3. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)

4. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

5. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14

2. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab;JAMA Network Open;2024-04-12

3. Multiple Sclerosis, Disease-Modifying Therapies, and Infections;Neurology Neuroimmunology & Neuroinflammation;2023-11

4. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients;Multiple Sclerosis Journal;2023-09-20

5. Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE);Multiple Sclerosis Journal;2023-06-15